ClinConnect ClinConnect Logo
Search / Trial NCT06982391

Compassion, Social Support, Flexibility, and Resilience Program for Women Surviving Breast Cancer

Launched by MEDIPOL UNIVERSITY · May 13, 2025

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

Resilience Psychological Flexibility Values Self As Compassionate Context Social Support Value Driven Committed Action Acceptance Defusion

ClinConnect Summary

Intervention studies aiming to increase psychological resilience in women with breast cancer after mastectomy are gaining increasing attention in the literature. Various studies highlight the positive effects of social support and psychological flexibility on the mental health of cancer patients. In particular, social support enhances the stress-coping capacity of cancer patients and strengthens their psychological resilience (Hulbert-Williams et al., 2015).

Acceptance and Commitment Therapy (ACT)-based interventions are considered an effective approach for coping with chronic illnesses. S...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Female participants aged between 18 and 65 years.
  • Participants who have undergone a mastectomy.
  • Participants who voluntarily agree to participate in the study.
  • Exclusion Criteria:
  • -

About Medipol University

Medipol University is a leading academic institution dedicated to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university conducts rigorous clinical trials aimed at improving patient outcomes and enhancing healthcare practices. Leveraging state-of-the-art facilities and a team of experienced researchers and healthcare professionals, Medipol University is committed to contributing to the global medical community through ethical research and the development of novel therapeutic strategies. The institution fosters an environment of academic excellence and integrity, ensuring that all trials adhere to the highest standards of safety and efficacy.

Locations

Istanbul, , Turkey

Patients applied

0 patients applied

Trial Officials

Ela Arı, Assistant Professor

Principal Investigator

Medipol University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported